Multi-Utilities

TIANJIN DEV

TIANJIN DEV released FY2025 9 Months earnings on March 30, 2026 (BJT), actual revenue HKD 2.457 B, actual EPS HKD 0.3599

TIANJIN DEV released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 738.81 M, actual EPS HKD 0.0388

TIANJIN DEV released FY2025 Q4 earnings on March 30 Pre-Market (BJT), actual revenue HKD 738.81 M, actual EPS HKD 0.0388

TIANJIN DEV released FY2025 Annual Earnings on March 30 Pre-Market (BJT), actual revenue HKD 3.196 B, actual EPS HKD 0.3988

TIANJIN DEV to Release FY2025 Earnings on March 30 Pre-Market (BJT)

TIANJIN DEV released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 859.29 M, actual EPS HKD 0.1605

TIANJIN DEV released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), actual revenue HKD 1.719 B, actual EPS HKD 0.321

TIANJIN DEV released FY2025 Q2 earnings on August 28 During-Market BJT, actual revenue HKD 859.29 M, actual EPS HKD 0.1605

TIANJIN DEV FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

Tianjin Development Secures HK$100 Million Loan Financing

TIANJIN DEV released FY2024 9-month earnings on March 28 (BJT), actual revenue 2.59 B HKD, actual EPS 0.3896 HKD

TIANJIN DEV released FY2024 Q3 earnings on March 28 (BJT), actual revenue 769.58 M HKD, actual EPS 0.1211 HKD

TIANJIN DEV released FY2024 annual earnings during market hours on March 28 (BJT), actual revenue 3.359 B HKD, actual EPS 0.5108 HKD

TIANJIN DEV released FY2024 Q4 earnings on March 28 During-Market (BJT), actual revenue 769.58 M HKD, actual EPS 0.1211 HKD

TIANJIN DEV FY2024 Annual Earnings Release on March 28, 2025 During-Market BJT

Tianjin Development Signs HKD 100 Million Revolving Loan Financing Letter

Tianjin Development Releases Interim Results for 2024

Tianjin Development (00882) subsidiary Lisheng Pharmaceutical announced its performance for the three months ended March 31, 2024

Tianjin Development expects annual net profit to increase by about 70%-80%

Tianjin Development releases 2023 annual performance report of Lisheng Pharmaceutical

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

00882

Tianjin Development Holdings has secured a HK$100 million revolving loan from a bank, with no fixed term and subject to lender review. A key condition is that Tianjin SASAC must maintain over 50% ownership in the company, emphasizing the importance of state control. Breaching this condition could lead to loan suspension or repayment demands, impacting funding stability. Tianjin Development is listed on the Hong Kong Stock Exchange and is controlled by the Tianjin SASAC, which holds a majority stake through subsidiaries.

Tip Ranks

Tianjin Development Secures HK$100 Million Revolving Loan Tied to State Majority Control

TIANJIN DEV announced its 2025 annual performance, with revenue of 3.196 billion yuan, a year-on-year decrease of 4.9%. It recorded a net profit of 428 million yuan, a decline of 21.9%, with earnings per share of 39.89 cents. The final dividend remains at 8.82 cents

AASTOCKS

"Performance" Tianjin Development's annual net profit is 428 million yuan, down 21.9%, with a final dividend of 8.82 cents

561700

560190

Tianjin Development Holdings (HK:0882) reported a slight decline in 2025 revenue to HK$3.20 billion and a drop in profit attributable to shareholders to HK$427.9 million. However, recurring profit rose 7.4% to HK$320.5 million, indicating improved operating performance. The board maintained total dividends at HK14 cents per share. Despite a decrease in gross profit to HK$938.0 million, increased other income and contributions from associates helped offset losses. Total profit for the year was HK$755.1 million, with a notable share going to non-controlling interests.

Bosera CSI All Share Electric Utilities ETF

Penghua CSI All Share Utilities ETF

Tianjin Development Holds Dividend Steady as Recurring Profit Rises Despite Lower Headline Earnings

159892

520880

516930

510660

159992

588130

159316

002393

520690

513700

512010

Tianjin Development's indirectly non-wholly-owned subsidiary Lishengpharma announced its full-year results for the year ended last December, with a revenue of RMB 1.392 billion, an increase of 4.2% year-on-year. The net profit was RMB 416 million, an increase of 125.6% year-on-year; earnings per share were RMB 1.62. A cash dividend of RMB 6.00 will be distributed for every 10 shares

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Lishengpharma

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB

Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend

Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend

Tianjin Development Holdings announced that its subsidiary, Tianjin Lisheng Pharmaceutical, reported strong preliminary results for 2025. Revenue increased by 4.23% year-on-year to RMB1.39 billion, while net profit attributable to shareholders surged 126.72% to RMB418 million. The growth was driven by market expansion and stronger product sales. Despite a slight decline in net assets per share, the results highlight the company's significant stake in China's healthcare market.

Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge

Tianjin Development Holdings has announced the sale of its entire stake in Benefo Financial Leasing for RMB264.93 million to Tianjin Capital. This transaction, conducted through its subsidiary Tianjin Tai Kang, will result in Benefo ceasing to be a subsidiary of Tianjin Development following regulatory approvals. The sale reflects a strategic adjustment in Tianjin Development's portfolio in the financial leasing sector, adhering to Hong Kong Listing Rules for discloseable transactions.

Tianjin Development Sells Entire Stake in Benefo Financial Leasing for RMB265 Million

TIANJIN DEV(00882.HK)

Tianjin Development Secures HK$100 Million Revolving Loan Tied to State Majority Control

"Performance" Tianjin Development's annual net profit is 428 million yuan, down 21.9%, with a final dividend of 8.82 cents

Tianjin Development Holds Dividend Steady as Recurring Profit Rises Despite Lower Headline Earnings

Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB

Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend

Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge

Tianjin Development Sells Entire Stake in Benefo Financial Leasing for RMB265 Million